Key Takeaways
- On June 10, ARK Invest offloaded 89,915 Robinhood shares valued at $7.53 million as the stock surged past $90
- The investment firm dumped 186,720 Iridium Communications shares worth $8.42 million, extending a recent selling streak
- ARK’s primary purchase was Kodiak AI, adding 141,502 shares totaling $868,822
- Robinhood board member Meyer Malka purchased more than $50 million worth of company shares recently, demonstrating strong insider belief
- Wall Street analysts maintain a Strong Buy rating on Robinhood with a consensus target price of $99.56
Cathie Wood’s ARK Invest executed multiple portfolio adjustments on June 10, 2026. The investment management firm reduced its stakes in Robinhood Markets, Iridium Communications, and Veracyte, while simultaneously increasing its exposure to Kodiak AI.
These transactions demonstrate ARK’s continuous portfolio rebalancing approach focused on disruptive innovation companies.
ARK’s Robinhood Position Trimming
On June 10, ARK divested 89,915 Robinhood shares valued at roughly $7.53 million. This divestment occurred while Robinhood stock surged beyond the $90 mark during morning trading hours, capping off an impressive rally.
Robinhood has demonstrated impressive momentum. The financial technology platform disclosed that total assets on its platform increased 9% month-over-month in May.
CEO Vlad Tenev revealed that Robinhood Securities secured regulatory authorization to function as an IPO underwriter. This capability opens up an additional revenue stream through underwriting fees.
The ARK divestment seems to represent strategic profit-taking instead of a fundamental shift in investment thesis. Insider transaction patterns paint a contrasting picture — board member Meyer Malka, who founded Ribbit Capital, acquired approximately $20.18 million worth of Robinhood shares on June 5 in a single transaction.
Malka’s aggregate purchases throughout the past week surpassed $50 million. Such substantial insider accumulation typically indicates robust internal optimism regarding the company’s trajectory.
According to TipRanks, Robinhood carries a Strong Buy consensus derived from 15 Buy recommendations and 3 Hold recommendations. The mean price objective of $99.56 suggests approximately 15% appreciation potential from present levels.
Iridium Reduction and Kodiak AI Accumulation
ARK’s most substantial individual transaction on that trading day involved divesting Iridium Communications holdings. The firm liquidated 186,720 shares generating $8.42 million in proceeds. This represented a continuation of selling activity from the previous session, indicating a systematic position reduction in Iridium.
ARK additionally offloaded 143,385 Veracyte shares worth $7.06 million. This transaction extended a week-long pattern of decreasing the genomic diagnostics company holding.
Regarding acquisitions, Kodiak AI emerged as the primary focus. ARK accumulated 141,502 shares for $868,822. This purchase aligns with ongoing Kodiak AI accumulation across ARK’s suite of exchange-traded funds.
Additional minor divestitures encompassed Roku, Twist Bioscience, Strata Critical Medical, 10X Genomics, Cerus, Pacific Biosciences, and Recursion Pharmaceuticals. Each of these transactions represented less than $1.7 million in value.
These portfolio adjustments exemplify ARK’s persistent approach of reallocating capital away from certain holdings while establishing positions in enterprises it perceives as synchronized with transformative technology trends.
Robinhood’s newly granted IPO underwriting authorization and its expanding platform assets position it as a stock that Wall Street analysts remain focused on approaching the latter half of 2026.
